SCHEMBL2215293

SCHEMBL2215293

CCNC(=O)c1ccc(C)c(-c2ccc3c(-c4ccc(C)c(F)c4)n[nH]c3n2)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.44
CHEK1 O14757 1/20 0.41
NAMPT P43490 2/20 0.40
MAP4K1 Q92918 1/20 0.38
LRRK2 Q5S007 1/20 0.37
DDR2 Q16832 4/20 0.37
FGFR1 P11362 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
LCK P06239 1/20 0.37
KIT P10721 1/20 0.37
KDR P35968 1/20 0.37
ABL1 P00519 1/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
F2 P00734 2/20 0.36
TRPA1 O75762 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215777 0.93 MAPK14 (0.41) MAPK14CHEK1NAMPTMAP4K1HDAC6
SCHEMBL2217263 0.91 MAPK14 (0.44) MAPK14CHEK1NAMPTABL1BCHE
SCHEMBL2216227 0.91 MAPT (0.42) MAPK14CHEK1DDR2FGFR1ABL1
SCHEMBL2215356 0.87 ACHE (0.49) MAPK14CHEK1NAMPTBCHEACHE
SCHEMBL2217915 0.86 KDM4E (0.47) MAPK14CHEK1DDR2FGFR1HDAC1
SCHEMBL2216103 0.85 TRPA1 (0.53) MAPK14CHEK1BCHEACHETRPA1
SCHEMBL2217549 0.85 MAPK1 (0.48) MAPK14NAMPTLRRK2DDR2FGFR1
SCHEMBL2216299 0.83 GSK3A (0.46) MAPK14NAMPTFGFR1HDAC1HDAC6
SCHEMBL4355419 0.79 KDM4E (0.47) MAPK14HDAC1HDAC6
SCHEMBL2215978 0.78 MAPK1 (0.45) MAPK14DDR2FGFR1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1709046-B1 P38 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-07-27 EP disclosed
EP-1709046-B1 P38 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-07-27 EP disclosed
US-20070161673-A1 P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-07-12 US disclosed
US-20070161673-A1 P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-07-12 US disclosed
US-20070161673-A1 P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161673-A1 P38 kinase inhibitors MAPK1, MAPK7, MAP3K1 MAPK14 14/4885CHEK1 682/4885NAMPT 1969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.